Could a common heart drug treat kaposi sarcoma?

NCT ID NCT05797662

Not yet recruiting Disease control Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether propranolol, a drug usually used for high blood pressure, can treat Kaposi sarcoma. About 25 children and adults will take propranolol pills for up to 24 weeks. Researchers will measure how many participants see their tumors shrink or disappear, and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: propranolol
What this could lead to: If it works, this could offer a low-cost, well-tolerated treatment option for Kaposi sarcoma, potentially reducing the need for chemotherapy.
What could go wrong: This is a small, early-phase trial with only 25 participants and no comparison group. Propranolol may not shrink tumors effectively, and side effects like low blood pressure or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kaposi's sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KAPOSI SARCOMA

Contacts and locations

Locations

Complexo Hospitalar Universitário Professor Edgard Santos

Salvador, Brazil
Fundación Huésped

Buenos Aires, Argentina
Instituto Nacional de Cancerologia

Mexico City, 14080, Mexico
Instituto Nacional de Câncer José de Alencar

Rio de Janeiro, 20231-050, Brazil
Uganda Cancer Institute

Kampala, Uganda
University of Zimbabwe College of Health Sciences

Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.